Something changed in antibody discovery that the field spent a decade waiting for. Antibodies designed on a computer, rather than fished from an immunized animal or a display library, are now being validated in the lab at binding rates and affinities that hold their own against molecules found the traditional way. What was a promising…
Shots:
The US FDA has approved Lerochol as an LDL-C lowering therapy for adults with hypercholesterolemia, including HeFH; US launch as a PFS is expected in spring 2026, with an autoinjector later in 2026, while EMA approval is anticipated in Jun 2026 alongside additional global regulatory filings
Approval was supported by the global P-III (LIBerate) trial, enrolling over 2,900 CVD patients and without…

